Synektik SA Adjusts Valuation Amid Strong Long-Term Growth and Profitability Metrics

Synektik SA, a midcap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in its evaluation. The company's valuation grade has shifted from very attractive to attractive, reflecting changes in its financial metrics. Currently, Synektik SA's P/E ratio stands at 19, while its Price to Book Value is noted at 9.94. The company exhibits a robust EV to EBIT of 14.20 and an EV to EBITDA of 12.59, indicating its operational efficiency. Additionally, the PEG ratio is reported at 0.28, suggesting a favorable growth outlook relative to its valuation. Despite a flat financial performance in the quarter ending December 2025, Synektik SA has demonstrated strong long-term fundamental strength, with a remarkable 69.14% CAGR growth in operating profits. The company maintains a net-debt-free status and has achieved an impressive Return on Capital Employed (ROCE) of 156.76%, highlighting its profitability. With a return on equity (ROE) of 52.29%, Synektik SA continues to trade at a discount compared to its peers, showcasing its competitive position in the market. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.